TYRO3 and colorectal carcinoma: TYRO3 function requires matrix metalloproteinase-2 (MMP-2) and bromodomain-containing protein 3 (BRD3), making selective inhibition of MMP-2 or BRD3 activity a potential strategy to ameliorate CRC malignancy[58].